Literature DB >> 26864644

LASIK surgery of granular corneal dystrophy type 2 patients leads to accumulation and differential proteolytic processing of transforming growth factor beta-induced protein (TGFBIp).

Ebbe Toftgaard Poulsen1, Nadia Sukusu Nielsen1, Morten M Jensen1, Esben Nielsen2, Jesper Hjortdal2, Eung Kweon Kim3,4, Jan J Enghild1,5.   

Abstract

More than 60 mutations in transforming growth factor beta-induced protein (TGFBIp) have been reported in humans causing a variety of phenotypic protein aggregates in the cornea, commonly termed corneal dystrophies. One mutation, generating an arginine to histidine amino acid substitution at position 124 in mature TGFBIp leads to granular corneal dystrophy type 2 (GCD2). Homozygous GCD2 cases develop massive protein accumulation early in life whereas heterozygous GCD2 cases become affected much later and generally with a much less severe outcome. However, if heterozygous GCD2 patients undergo laser-assisted in situ keratomileusis (LASIK) surgery protein accumulation is accelerated and they develop massive protein accumulations a few years after surgery. Here, we present the protein profile of aggregate-containing corneal tissue from GCD2 patients with a history of LASIK surgery using LC-MS/MS. Label-free quantification of corneal extracellular matrix proteins showed accumulation of TGFBIp. This was supported by 2DE and immunoblotting against TGFBIp that revealed the accumulation of full-length TGFBIp. In addition, a high molecular weight TGFBIp complex was more apparent in GCD2 patients after LASIK surgery, which may be important for the disease progression. Lastly, 2DE also revealed differential processing between GCD2 patients with a history of LASIK surgery when compared to healthy individuals.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  2DE immunoblotting; Biomedicine; Cornea; Granular corneal dystrophy type 2; TGFBIp; XIC label-free quantification

Mesh:

Substances:

Year:  2016        PMID: 26864644     DOI: 10.1002/pmic.201500287

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  6 in total

1.  Deterioration of Avellino corneal dystrophy in a Chinese family after LASIK.

Authors:  Xue Jiang; Hong Zhang
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

2.  Prevalence of granular corneal dystrophy type 2-related TGFBI p.R124H variant in a South Korean population.

Authors:  Jong Eun Park; Sun Ae Yun; Eun Youn Roh; Jong Hyun Yoon; Sue Shin; Chang-Seok Ki
Journal:  Mol Vis       Date:  2021-05-08       Impact factor: 2.367

3.  Differential profile of protein expression on human keratocytes treated with autologous serum and plasma rich in growth factors (PRGF).

Authors:  Eduardo Anitua; María de la Fuente; Francisco Muruzabal; Ronald Mauricio Sánchez-Ávila; Jesús Merayo-Lloves; Mikel Azkargorta; Felix Elortza; Gorka Orive
Journal:  PLoS One       Date:  2018-10-12       Impact factor: 3.240

4.  The serine protease HtrA1 cleaves misfolded transforming growth factor β-induced protein (TGFBIp) and induces amyloid formation.

Authors:  Ebbe Toftgaard Poulsen; Nadia Sukusu Nielsen; Carsten Scavenius; Emilie Hage Mogensen; Michael W Risør; Kasper Runager; Marie V Lukassen; Casper B Rasmussen; Gunna Christiansen; Mette Richner; Henrik Vorum; Jan J Enghild
Journal:  J Biol Chem       Date:  2019-06-13       Impact factor: 5.157

5.  A pathogenic variant in the transforming growth factor beta I (TGFBI) in four Iranian extended families segregating granular corneal dystrophy type II: A literature review.

Authors:  Aliasgar Mohammadi; Azam Ahmadi Shadmehri; Mahnaz Taghavi; Gholamhossein Yaghoobi; Mohammad Reza Pourreza; Mohammad Amin Tabatabaiefar
Journal:  Iran J Basic Med Sci       Date:  2020-08       Impact factor: 2.699

6.  TGF-β1 enhanced myocardial differentiation through inhibition of the Wnt/β-catenin pathway with rat BMSCs.

Authors:  Yang Lv; Xiu-Juan Li; Hai-Ping Wang; Bo Liu; Wei Chen; Lei Zhang
Journal:  Iran J Basic Med Sci       Date:  2020-08       Impact factor: 2.699

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.